CL2017000054A1 - Indoles funcionalizados y sustituidos como agentes anti-cáncer - Google Patents

Indoles funcionalizados y sustituidos como agentes anti-cáncer

Info

Publication number
CL2017000054A1
CL2017000054A1 CL2017000054A CL2017000054A CL2017000054A1 CL 2017000054 A1 CL2017000054 A1 CL 2017000054A1 CL 2017000054 A CL2017000054 A CL 2017000054A CL 2017000054 A CL2017000054 A CL 2017000054A CL 2017000054 A1 CL2017000054 A1 CL 2017000054A1
Authority
CL
Chile
Prior art keywords
indoles
functionalized
substituted
cancer agents
compounds
Prior art date
Application number
CL2017000054A
Other languages
English (en)
Inventor
Andrew Heaton
Eleanor Eiffe
Narender Pottabathini
Peter Gunning
Original Assignee
Novogen ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd filed Critical Novogen ltd
Publication of CL2017000054A1 publication Critical patent/CL2017000054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS ANTITROPOMIOSINA, PROCESOS PARA SU PREPARACIÓN, Y MÉTODOS PARA TRATAR O PREVENIR UNA ENFERMEDAD O TRASTORNO, TAL COMO UNA ENFERMEDAD PROLIFERATIVA (DE PREFERENCIA CÁNCER), USANDO COMPUESTOS DE LA INVENCIÓN.</p>
CL2017000054A 2014-07-16 2017-01-09 Indoles funcionalizados y sustituidos como agentes anti-cáncer CL2017000054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462025207P 2014-07-16 2014-07-16

Publications (1)

Publication Number Publication Date
CL2017000054A1 true CL2017000054A1 (es) 2017-06-23

Family

ID=55077744

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000054A CL2017000054A1 (es) 2014-07-16 2017-01-09 Indoles funcionalizados y sustituidos como agentes anti-cáncer

Country Status (16)

Country Link
US (1) US20170152226A1 (es)
EP (1) EP3169683A4 (es)
JP (1) JP2017520612A (es)
KR (1) KR20170031097A (es)
CN (1) CN106661005A (es)
AU (3) AU2015227454B2 (es)
BR (1) BR112017000714A2 (es)
CA (1) CA2952557A1 (es)
CL (1) CL2017000054A1 (es)
CO (1) CO2017000065A2 (es)
IL (1) IL250074A0 (es)
MX (1) MX2017000613A (es)
PH (1) PH12016502607A1 (es)
RU (1) RU2017104856A (es)
SG (1) SG11201610195UA (es)
WO (1) WO2016008011A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016122731A (ru) * 2013-11-25 2018-01-09 Новоген Лтд Функционализированные и замещенные индолы в качестве противораковых агентов
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR101862765B1 (ko) 2017-04-21 2018-05-30 한국화학연구원 N-아릴사이클릭아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US20210040118A1 (en) * 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110128415B (zh) * 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
CN110229091B (zh) * 2019-06-21 2022-11-22 天津科技大学 具有白三烯a4水解酶抑制作用的1，5-二取代吲哚衍生物及应用
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN113121429B (zh) * 2020-01-15 2024-04-26 鲁南制药集团股份有限公司 一种c-Met激酶抑制剂及其制备方法和应用
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
CN113149897B (zh) * 2021-03-24 2023-10-31 福建省中科生物股份有限公司 一种2,6-取代-4-氧基萜酚吡啶类化合物及其制备方法和用途
WO2023049953A1 (en) * 2021-09-30 2023-04-06 TroBio Therapeutics Pty Ltd Substituted indole compounds and the use thereof
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
AU2023412594A1 (en) * 2022-12-23 2025-07-10 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Parp1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101553467B (zh) * 2007-01-08 2011-12-07 苏文生命科学有限公司 5-(杂环基)烷基-n-(芳基磺酰基)吲哚化合物及其作为5-ht6配体的用途
ES2749504T3 (es) * 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
RU2016122731A (ru) * 2013-11-25 2018-01-09 Новоген Лтд Функционализированные и замещенные индолы в качестве противораковых агентов

Also Published As

Publication number Publication date
CN106661005A (zh) 2017-05-10
RU2017104856A (ru) 2018-08-16
JP2017520612A (ja) 2017-07-27
EP3169683A4 (en) 2017-11-22
KR20170031097A (ko) 2017-03-20
CA2952557A1 (en) 2016-01-21
PH12016502607A1 (en) 2017-04-24
EP3169683A1 (en) 2017-05-24
MX2017000613A (es) 2017-04-27
AU2017254894A1 (en) 2017-11-23
AU2016200541A1 (en) 2016-02-18
US20170152226A1 (en) 2017-06-01
IL250074A0 (en) 2017-03-30
WO2016008011A1 (en) 2016-01-21
SG11201610195UA (en) 2017-01-27
CO2017000065A2 (es) 2017-05-19
BR112017000714A2 (pt) 2018-01-09
AU2015227454B2 (en) 2016-02-25
AU2015227454A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2017001171A1 (es) Peptidos macrocíclicos útiles como inmunomoduladores
LT4001311T (lt) Anti-pd-l1/pd-1 deriniai, skirti navikų gydymui
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
EA201790173A1 (ru) Антитела, связывающие axl
CL2017000310A1 (es) Anticuerpos anti tigit
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EP4036099C0 (en) Methods for the preparation of ribosides
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
EP3186278A4 (en) Internalizing moieties for treatment of cancer
PL3377516T3 (pl) Kompozycja do leczenia nowotworu
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
PH12016500967A1 (en) Functionalised and substituted indoles as anti-cancer agents
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
IL265751B (en) Immunogenic compounds for cancer therapy
EP3191128A4 (en) Uses of anti-her3 antibodies for treating cancer
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
CO2017010143A2 (es) Procesos para preparar fluorocetólidos
FR3022234B1 (fr) Procede de preparation de nanofils de silicium.